Skip to main content

Advertisement

Table 3 Determinants of antipsychotic prescribing using multivariate logistic GEE estimation (N = 199,549)

From: Antipsychotic prescribing for Alzheimer’s disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study

  Adjusted odds ratio 95% confidence interval p value
Year
 2010 1   
 2011 1.10 1.05–1.15 <0.001
 2012 1.12 1.06–1.17 <0.001
 2013 1.16 1.10–1.21 <0.001
 2014 1.23 1.17–1.30 <0.001
MMSE
 0–10 2.63 2.51–2.75 <0.001
 11–20 1.56 1.51–1.62 <0.001
 21–30 1   
Age at first consultation with the diagnosis
 ≤75 years 1   
 76–80 years 0.91 0.86–0.96 0.001
 81–85 years 0.85 0.81–0.90 <0.001
 >85 years 0.80 0.76–0.84 <0.001
Gender
 Female 1   
 Male 1.34 1.30–1.39 <0.001
Education (years)
 0 1   
 1–5 0.87 0.82–0.92 <0.001
 6–12 0.84 0.78–0.89 <0.001
 ≥13 0.77 0.70–0.84 <0.001
 Unknown 0.96 0.89–1.03 0.224
Type of centre
 Memory clinic 1   
 Regional reference memory centre 0.83 0.77–0.91 <0.001
 Private practice neurologist 0.60 0.42–0.86 0.006
Antidepressant
 No 1   
 Yes 1.77 1.71–1.84 <0.001
Hypnotic
 No 1   
 Yes 1.91 1.82–2.01 <0.001
Anxiolytic
 No 1   
 Yes 2.42 2.33–2.51 <0.001
NMDA antagonist
 No 1   
 Yes 1.32 1.28–1.36 <0.001
Lifestyle
 Community-living 1   
 Long-term care facility 2.01 1.94–2.09 <0.001
Patient's location
 Within 50 km from memory consultation 1   
 >50 km from memory consultation 0.93 0.87–1.00 0.036
Years × type of centera    <0.001
  1. GEE generalized estimating equations, MMSE Mini Mental state examination, NMDA N-methyl-D-aspartate receptor
  2. aSignificant interaction entered in the model